Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Enhances Bioavailability of Orally Administered APIs
Lexaria is a global innovator in drug delivery platformsThe company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeuticsBioavailability is the fraction of a drug that reaches the site of action or systemic circulationWhile drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailabilityDehydraTECH enhances the bioavailability of APIs, in part, by bypassing first-pass liver processing Global innovator Lexaria Bioscience (NASDAQ: LEXX) has built a reputation as a developer of drug delivery platforms, the most notable of which is the patented DehydraTECH(TM)…

